1 BTC
=
- USD
Elanco Animal Health Incorporated Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Elanco Animal Health Incorporated Common Stock
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Market Statistics
Trading Metrics
How to Buy ELAN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ELAN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesElanco Animal Health (NYSE: ELAN) shares rose 9.33% following better-than-expected Q1 earnings of 40 cents per share (vs. 35 cents consensus) and $1.37 billion in sales (vs. $1.29 billion consensus). The company raised full-year guidance and reported strong growth across both Pet Health and Farm Animal segments, driven by new product launches and market expansion. Emergency use authorization approvals for Negasunt Powder and Tanidil also supported the stock movement.
PRISM MarketView launched the PRISM PetCare Index to track publicly traded companies driving growth in the global pet care sector, projected to exceed $350 billion. The index includes companies advancing veterinary services, pet pharmaceuticals, insurance, diagnostics, and premium nutrition. Key companies highlighted include Elanco Animal Health, Chewy, and Trupanion, which are positioned to benefit from increasing consumer spending on pet healthcare, preventative services, and subscription-based offerings.
Zoetis is set to report Q4 2025 earnings on Feb. 12 after disappointing guidance last quarter caused an 11% stock decline. While the company has beaten earnings in four consecutive quarters and lowered expectations could set up positive surprises, investors remain concerned about persistent macro headwinds affecting its livestock business and osteoarthritis treatments. The analyst recommends long-term investors wait until after earnings to enter a position, as further downside risk exists if guidance disappoints again.
The global canine glucosamine supplement market is experiencing rapid growth, expanding from USD 236.44 million in 2025 to USD 257.55 million in 2026, with a projected CAGR of 7.27% through 2032, reaching USD 386.54 million. Market growth is driven by increased pet ownership, higher consumer spending on veterinary wellness, product innovation in formats like chewables and liquids, and omnichannel distribution strategies. Key opportunities include palatability improvements, multi-ingredient formulations, and age-specific product targeting.
The global canine vaccines market is projected to grow from USD 2.05 billion in 2025 to USD 3.45 billion by 2033, with a CAGR of 6.79%. Growth is driven by rising pet ownership, increased awareness of preventive animal healthcare, and higher veterinary spending. Core vaccines and rabies vaccines lead by market share, while combination vaccines and Lyme disease vaccines show the fastest growth. North America dominates with 36.5% market share, while Asia Pacific is expected to grow fastest at 8.22% CAGR.
